BLA 019640 · Lilly
Humatrope
Somatropin · Injection
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Nov 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Oct 16, 1986
Approved uses
9
Original approval plus efficacy supplements
Registered trials
540
176 Phase 3, 31 recruiting
FAERS reports
11,846
6,001 serious, 475 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 20, 2026.
HUMATROPE is a recombinant human growth hormone indicated for: Pediatric Patients: growth failure due to inadequate secretion of endogenous growth hormone (GH); short stature associated with Turner syndrome; Idiopathic Short Stature (ISS), height standard deviation score (SDS) <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range; short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency; short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years of age. ( 1.1 ) Adult Patients: replacement of endogenous GH in adults with GH deficiency. ( 1.2 ) 1.1 Pediatric Patients HUMATROPE is indicated for the treatment of pediatric patients with: growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Turner syndrome, Idiopathic Short Stature (ISS), height standard deviation score (SDS) <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years of age. 1.2 Adult Patients HUMATROPE is indicated for the replacement of endogenous GH in adults with GH deficiency.
Mechanism: Somatropin binds to dimeric GH receptors located within the cell membranes of target tissue cells. This interaction results in intracellular signal transduction and subsequent induction of transcription and translation of GH-dependent proteins including IGF-1, IGF BP-3 and acid-labile subunit. Somatropin has direct tissue and metabolic effects or mediated indirectly by IGF-1, including stimulation of chondrocyte differentiation, and proliferation, stimulation of hepatic glucose output, protein synthesis and lipolysis. Somatropin stimulates skeletal growth in pediatric patients with GHD as a...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 12, 2009 Supplement 68 · Efficacy LabelLetter
- Nov 1, 2006 Supplement 58 · Efficacy LetterLabel
- Oct 12, 2005 Supplement 45 · Efficacy LabelLetter
- Jul 25, 2003 Supplement 33 · Efficacy LetterLabelReview
- Mar 11, 1997 Supplement 18 · Efficacy Review
- Aug 1, 1996 Supplement 13 · Efficacy
- Apr 15, 1994 Supplement 9 · Efficacy · priority review
- May 10, 1989 Supplement 2 · Efficacy
- Oct 16, 1986 Original approval · Type 5 - New Formulation or New Manufacturer · priority review
5 products under this application
- HUMATROPE · SOMATROPIN 2MG/VIAL · INJECTABLE, INJECTION · Discontinued
- HUMATROPE · SOMATROPIN 12MG/VIAL · INJECTABLE, INJECTION · Prescription
- HUMATROPE · SOMATROPIN 5MG/VIAL · INJECTABLE, INJECTION · Prescription
- HUMATROPE · SOMATROPIN 24MG/VIAL · INJECTABLE, INJECTION · Prescription
- HUMATROPE · SOMATROPIN 6MG/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Somatropin" as an intervention, any sponsor and status, largest first.
- Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in ChildrenStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT03290235 · 1,500 participants (planned) · Start Mar 1, 2017 · Primary completion Oct 2020
Drug: PEG-somatropin · For: Growth Retardation
Sites: Wuhan, China
- Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and RehabilitationPivotal-lookingTerminated
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00675714 · 1,126 participants · Start Jan 2004 · Primary completion Sep 2018
Drug: Humatrope; Ketoconazole and 5 more · For: Burns
Sites: Galveston, Texas
- Current Status of Islet Alpha Cell Function in Patients with Type 2 DiabetesPivotal-lookingRecruiting
Nanjing First Hospital, Nanjing Medical UniversityAcademic, hospital or other
NCT06825182 · 1,000 participants (planned) · Start Nov 7, 2024 · Primary completion Aug 1, 2025
Drug: Outpatient newly diagnosed type 2 diabetes subjects; Inpatient newly diagnosed type 2 diabetes subjects · For: Type 2 Diabetes Mellitus
Sites: Nanjing, China
- Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone DeficiencyStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT03249480 · 900 participants (planned) · Start Jan 2015 · Primary completion Aug 2017
Drug: PEG-somatropin · For: Growth Hormone Deficiency
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 28 sites in all
- Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency ChildrenStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT02314676 · 900 participants (planned) · Start Nov 2014 · Primary completion Jul 2017
Drug: PEG-somatropin · For: Dwarfism, Pituitary
Sites: Wuhu, China; Hangzhou, China
- Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone DeficiencyPivotal-lookingStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT02908958 · 900 participants (planned) · Start Nov 2014 · Primary completion Jun 2017
Drug: PEG-somatropin; PEG-somatropin · For: Growth Hormone Deficiency
Sites: Hefei, China; Wuhu, China; Xiamen, China · 22 sites in all
- The Effect of Somatropin Treatment in Adult Patients on Chronic DialysisPivotal-lookingTerminated
Novo Nordisk A/SNovo Nordisk (NVO)
NCT00503698 · 712 participants · Start Jul 2007 · Primary completion Dec 2008
Drug: somatropin; placebo · For: Chronic Kidney Disease; End-Stage Renal Disease
Sites: Alexander City, Alabama; Birmingham, Alabama; Madison, Alabama · 381 sites in all
- Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort StudyPivotal-lookingCompleted
ShangHai Ji Ai Genetics & IVF InstituteAcademic, hospital or other
NCT05574894 · 692 participants · Start Jan 1, 2021 · Primary completion Jun 30, 2022
Drug: Growth hormone; GnRH antagonist · For: Growth Hormone; Advanced Maternal Age; PGT-A
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- incorrect dose administered1,016
- injection site pain643
- off label use511
- headache481
- drug dose omission431
- fatigue424
- underdose407
- device leakage342
- malaise325
- wrong technique in product usage process260
- drug ineffective244
- drug dose omission by device222
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 148 |
| 2005 | 161 |
| 2006 | 156 |
| 2007 | 212 |
| 2008 | 197 |
| 2009 | 350 |
| 2010 | 277 |
| 2011 | 327 |
| 2012 | 388 |
| 2013 | 197 |
| 2014 | 272 |
| 2015 | 2,473 |
| 2016 | 575 |
| 2017 | 531 |
| 2018 | 622 |
| 2019 | 782 |
| 2020 | 710 |
| 2021 | 440 |
| 2022 | 538 |
| 2023 | 854 |
| 2024 | 798 |
| 2025 | 505 |
| 2026 | 333 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Humatrope (Somatropin)
2024 spending
$6.1M
Beneficiaries
286
1,889 claims
Per beneficiary
$21,374
$1,462.35 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,960,925 |
| 2021 | $6,457,216 |
| 2022 | $6,124,826 |
| 2023 | $6,210,736 |
| 2024 | $6,113,003 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.
Deal CL, Steelman J, Vlachopapadopoulou E, et al. · J Clin Endocrinol Metab 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.
Thornton PS, Maniatis AK, Aghajanova E, et al. · J Clin Endocrinol Metab 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency.
Kildemoes RJ, Hollensen C, Biller BMK, et al. · Eur J Endocrinol 2022 · Clinical Trial
- Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results.
Maniatis AK, Thornton PS, Nadgir UM, et al. · Horm Res Paediatr 2026 · Multicenter Study, Clinical Trial, Phase III
- Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study.
Gomez R, Lamoureux R, Turner-Bowker DM, et al. · Front Endocrinol (Lausanne) 2023 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Linear growth response to recombinant human growth hormone in children with growth hormone deficiency.
Shih KC, Ho LT, Kuo HF, et al. · Zhonghua Yi Xue Za Zhi (Taipei) 1994 · Clinical Trial, Controlled Clinical Trial
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.